1. Home
  2. BBCP vs QTTB Comparison

BBCP vs QTTB Comparison

Compare BBCP & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Concrete Pumping Holdings Inc.

BBCP

Concrete Pumping Holdings Inc.

HOLD

Current Price

$9.01

Market Cap

490.8M

ML Signal

HOLD

Logo Q32 Bio Inc.

QTTB

Q32 Bio Inc.

HOLD

Current Price

$14.36

Market Cap

450.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BBCP
QTTB
Founded
1983
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Engineering & Construction
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
490.8M
450.1M
IPO Year
2017
2018

Fundamental Metrics

Financial Performance
Metric
BBCP
QTTB
Price
$9.01
$14.36
Analyst Decision
Buy
Strong Buy
Analyst Count
2
1
Target Price
$8.25
$13.00
AVG Volume (30 Days)
127.0K
393.8K
Earning Date
06-04-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
136.78
EPS
N/A
N/A
Revenue
$392,867,000.00
$53,737,000.00
Revenue This Year
$4.90
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.56
$1.62
52 Week High
$12.19
$23.57

Technical Indicators

Market Signals
Indicator
BBCP
QTTB
Relative Strength Index (RSI) 36.40 41.40
Support Level $8.89 $10.68
Resistance Level $12.08 $14.93
Average True Range (ATR) 0.33 0.76
MACD 0.00 -0.22
Stochastic Oscillator 28.99 5.56

Price Performance

Historical Comparison
BBCP
QTTB

About BBCP Concrete Pumping Holdings Inc.

Concrete Pumping Holdings Inc is a provider of concrete pumping services and concrete waste management services in the fragmented United States and United Kingdom markets. Its large fleet of specialized pumping equipment and trained operators enables it to deliver concrete placement solutions. The company's operating segments include U.S. Concrete Pumping, U.K. Operations, and U.S. Concrete Waste Management Services, with the majority of revenue generated from the U.S. Concrete Pumping segment. Geographically, it operates in the United States and the United Kingdom, generating majority of its revenue from the United States.

About QTTB Q32 Bio Inc.

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).

Share on Social Networks: